HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Desirudin: a review of the pharmacology and clinical application for the prevention of deep vein thrombosis.

Abstract
Direct thrombin inhibitors (DTIs) are an emerging class of anticoagulants in routine clinical practice, although they have been under investigation for quite some time. Desirudin (Iprivask®, Canyon Pharmaceuticals™) is a recombinant hirudin derivative that directly inhibits free and fibrin-bound thrombin. Desirudin was the first DTI approved for deep vein thrombosis (DVT) prophylaxis in Europe (Revasc®) and is the newest injectable DTI commercially available in the USA. Desirudin is one of the few nonheparin subcutaneous drugs that has demonstrable efficacy for DVT prophylaxis. Subcutaneous desirudin has been shown to be more effective than both subcutaneous unfractionated heparin and enoxaparin, with comparable bleeding rates in the prevention of DVT in patients undergoing elective hip replacement. Desirudin also offers the advantage of a fixed dosing regimen while being less immunogenic than unfractionated heparin. However, owing to its pharmacokinetic properties, patients with renal dysfunction require dosing modifications. The favorable profile shown with desirudin thus far will allow its clinical use to grow and will promote further investigation into broadening its clinical applications.
AuthorsThomas J Graetz, Bethany R Tellor, Jennifer R Smith, Michael S Avidan
JournalExpert review of cardiovascular therapy (Expert Rev Cardiovasc Ther) Vol. 9 Issue 9 Pg. 1101-9 (Sep 2011) ISSN: 1744-8344 [Electronic] England
PMID21932952 (Publication Type: Comparative Study, Journal Article, Review)
Chemical References
  • Anticoagulants
  • Antithrombins
  • Hirudins
  • Recombinant Proteins
  • desirudin
Topics
  • Animals
  • Anticoagulants (administration & dosage, pharmacology, therapeutic use)
  • Antithrombins (administration & dosage, pharmacology, therapeutic use)
  • Dose-Response Relationship, Drug
  • Hemorrhage (chemically induced)
  • Hirudins (administration & dosage, pharmacology)
  • Humans
  • Recombinant Proteins (administration & dosage, pharmacology, therapeutic use)
  • Renal Insufficiency (complications)
  • Venous Thrombosis (prevention & control)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: